Eurofins Viracor BioPharma is a trusted provider of drug development solutions to pharmaceutical and contract research organizations. We offer complex/esoteric testing and assay development, to help advance your Phase 1-4 clinical trials through trusted partnership, scientific excellence, and exceptional service.
For more than 40 years, Eurofins Viracor BioPharma has been dedicated to helping clients by providing high-quality, accurate results to evaluate the effects of drug candidates across all major therapeutic categories. We offer broad experience in molecular infectious disease testing, vaccine safety and efficacy assessment, immunogenicity, cell-based assays, allergy/hypersensitivity, and biomarker analysis. Our validated test list includes more than 3,000 assays, with new custom assays developed on a continual basis, in response to client needs.
Expertise
We’re driven to partner with you to solve difficult scientific problems, complementing your strategies with expertise in complex method development on multiple technology platforms, validation, and transfer. Our Research & Development team serves as an extension of your laboratory, with unique skills in technology platform selection and protocol design.
Agility
Eurofins Viracor BioPharma leverages over 16 different technology platforms and accepts a broad range of specimen types, widening our capabilities and enabling us to customize testing to your exact needs for your clinical trial combined with the scalability to manage trials of any size. We adhere to GCLP guidelines.
Speed
Our high-throughput laboratory can support your clinical trials with the capacity to process large sample volumes quickly, support studies with short set up timelines and provide rapid turnaround times. Our project managers and scientists act as part of your team – going above and beyond to get you the results you need when you need them. Accelerating your vaccine, compound, immune therapy or biological from bench to market.
Utilizing Quantitative PCR for the Assessment of AAV Shedding
Watch this webinar discussing the development and validation of a sensitive, reproducible, and robust client-specific AAV qPCR assay designed for viral shedding studies.
Merck Recognizes Eurofins Viracor BioPharma with Award
Merck recently presented Eurofins Viracor BioPharma with a "Top Performer" award in recognition for their dedication and successful execution of the PCR assay validation supporting a recent clinical development project.
A Performance Evaluation Study Utilizing Bone Marrow and PBMC Samples
Assessing ddPCR Efficacy in Detecting Rare BRAF Mutations
The ddPCR technology partitions samples into numerous droplets, facilitating PCR amplification within each droplet and subsequent quantification. This innovative approach has paved the way for targeted therapies like BRAF inhibitors, designed to disrupt aberrant signaling and inhibit cancer cell growth. Identifying the BRAFV600E mutation not only enhances our understanding of cancer at the molecular level but also enables personalized medicine strategies, providing more precise and effective treatment options based on individual genetic profiles. As research progresses, the significance of this mutation in both diagnosis and therapeutic interventions remains pivotal in oncology.
In this white paper, we outline the validation experiments and performance attributes of quantitative BRAF V600E mutation detection assays conducted using ddPCR at Eurofins Viracor Biopharma.
5 Key Pitfalls to Avoid for Successful Vaccine Trials
John Holtzclaw, Scientific Advisor at Eurofins Viracor BioPharma
Vaccine clinical trials require precise planning and expert navigation to achieve meaningful outcomes. John Holtzclaw, Scientific Advisor at Eurofins Viracor BioPharma Services, shares insights into five critical pitfalls and strategies to avoid them.
By focusing on these areas, vaccine trials can be streamlined, leading to more reliable outcomes. Adaptability, careful planning, and local considerations are key to overcoming these challenges.
